<div id="readability-page-1"><div> <div> Rise in prevalence of chronic diseases and surge in geriatric population are the major factors that drive the growth of the regenerative medicine market. , /PRNewswire/ -- Allied Market Research published a report, titled, &#34;Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering and Small Molecule &amp; Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033&#34;. According to the report, the regenerative medicine market was valued at $32.1 billion in 2023, and is estimated to reach $531.7 billion by 2033, growing at a CAGR of 32.4% from 2024 to 2033. Request Sample of the Report on Nuclear Medicine Equipment Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/391 Factors driving the growth of the market However, high costs of treatment hinder the market growth. Moreover, technological advancements and regulatory support and funding offer lucrative opportunities for the expansion of the global regenerative medicine market. The cell therapy segment to maintain its leadership status during the forecast period By product type, the cell therapy segment generated the highest revenue in the regenerative medicine market in 2023. Cell therapy is an important part of regenerative medicine. It helps treat different diseases and injuries. It helps improve patient outcomes and quality of life as well. The biological segment to maintain its leadership status during the forecast period By material, the biological segment generated the highest revenue in the regenerative medicine market in 2023. Biologically derived materials provide a supportive environment for cell growth, differentiation, and tissue regeneration. Their biocompatibility and bioactivity make them ideal components for promoting tissue repair and regeneration in various medical applications, driving their demand in regenerative therapies. The oncology segment to maintain its leadership status during the forecast period By application, the oncology segment generated the highest revenue in the regenerative medicine market in 2023. The rise in prevalence of chronic diseases, particularly cancer, makes way for the need for regenerative medicine. Hospitals, cancer treatment centers, and others adopt regenerative medicine as it offers effective treatment outcomes. Thus, the sector is poised to experience growth in the upcoming years. Regional Outlook From a regional perspective, North America and Europe are expected to maintain market leadership due to strong research infrastructure and reimbursement frameworks. However, Asia-Pacific is projected to grow at a faster pace, driven by expanding healthcare access, rising clinical trial activity, and government support for biotechnology development. Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/391 Key Players <ul type="disc"> <li>Stryker Corporation</li> <li>Zimmer Biomet Holdings Inc.</li> <li>Medtronic Plc.</li> <li>Athersys Inc.</li> <li>Stem Cell Inc. (Bioheart Inc.)</li> <li>Organogenesis Inc.</li> <li>Integra Lifesciences Holdings Corporation</li> <li>Acelity Holdings Inc.</li> <li>Isto Biologics (Isto Biologics Medical Systems Inc.)</li> <li>CryoLife Inc.</li> </ul> The report provides a detailed analysis of these key players in the global regenerative medicine market. These players have adopted different strategies such as expansion, acquisition, product approval, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. Recent Industry Development <ul type="disc"> <li>In December 2023, The University of Toronto's Medicine by Design initiative and CCRM, a non-profit organization that supports the development and commercialization of regenerative medicines, announced a launch of new strategic alliance to unlock Toronto's potential as a world-leading ecosystem for regenerative medicine. The goal of the alliance is to create coordinated, end-to-end capacity that spans discovery through clinical translation and commercialization.</li> <li>In January 2021, Integra LifeSciences Holdings Corporation, a global leader in regenerative tissue technologies and neurosurgical solutions, announced that it has completed the previously disclosed acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers' most pressing clinical challenges.</li> <li>In August 2023, Gilead Sciences and Tentarix Biotherapeutics entered into three multi-year collaborations to leverage Tentarix's Tentacles platform for the discovery and development of innovative, multi-functional protein-based therapies for cancer and inflammatory diseases.</li> <li>In December 2022, Integra LifeSciences Holdings Corporation, a global leader in regenerative tissue technologies and neurosurgical solutions, announced that it has successfully completed its acquisition of Surgical Innovation Associates (SIA). This acquisition is a highly strategic move to enable us to achieve our aspirations to become a global leader and innovator of implant-based breast reconstruction (IBBR) procedures.</li> </ul> How Is the Regenerative Medicine Market Performing Compared to Previous Years? The regenerative medicine market is experiencing growth owing to advancements in in cell therapy, gene therapy, and tissue engineering. Several regenerative therapies have moved from early-stage trials to late-stage development and commercialization. This progress has increased investor confidence and attracted significant funding from both public and private sources. Healthcare providers are adopting regenerative medicine as an alternative to traditional treatments that focus on symptom management rather than tissue repair or regeneration. Compared to previous years, hospitals and specialty clinics now have greater access to approved therapies and clinical evidence supporting their effectiveness. This leads to wider acceptance among clinicians and patients. Further, collaborations between biotechnology companies, academic institutions, and pharmaceutical firms have gained traction. These partnerships have accelerated product development and improved scalability. For Purchase Related Queries/Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/391 What Is the Regenerative Medicine Market Growth Forecast and CAGR Outlook? The regenerative medicine market is expected to experience strong growth during the forecast period. This is attributed to increase in clinical adoption and ongoing innovation. Oncology, rare genetic disorders, and degenerative conditions are expected to remain the largest contributors to revenue growth. The market is anticipated to experience growth as more number of therapies receive regulatory approval. Surge in healthcare investment and favorable regulatory initiatives create lucrative growth opportunities for the market during the forecast period. Governments and regulatory agencies are focusing on creation of increase in approval pathways for regenerative therapies. These initiatives help reduce time to market and encourage innovation. The report, published by Allied Market Research, focuses on market dynamics and key trends of the regenerative medicine market analysis. The study provides competitive landscape analysis of the key players to understand the adopted strategies and competitive intensity of competitors. It also offers a study of threat of new entrants, and bargaining power of buyers, on the regenerative medicine market outlook. Explore AMR's Extensive Ongoing Coverage on Life Science Industry: Weight Management Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 India IVF Services Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 Albumin Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 At-home Genetic Testing Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 Medical Software Market: Global Opportunity Analysis and Industry Forecast, 2023-2032 AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. Buy Now: https://bit.ly/3ZZW1Yz About Allied Market Research: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of &#34;Market Research Reports&#34; and &#34;Business Intelligence Solutions.&#34; AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials &amp; Chemicals, Construction &amp; Manufacturing, Food &amp; Beverages, Energy &amp; Power, Semiconductor &amp; Electronics, Automotive &amp; Transportation, ICT &amp; Media, Aerospace &amp; Defense, and BFSI. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact David Correa 1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA. Toll Free: +1-800-792-5285 Int'l: +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 [email protected] Web: https://www.alliedmarketresearch.com Logo - https://mma.prnewswire.com/media/636519/5781865/Allied_Market_Research_Logo.jpg SOURCE Allied Market Research <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjEwJk5ld3NJdGVtSWQ9SU84NDg1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMTAxMTU4UFJfTkVXU19VU1BSX19fX19JTzg0ODU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjEwJk5ld3NJdGVtSWQ9SU84NDg1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMTAxMTU4UFJfTkVXU19VU1BSX19fX19JTzg0ODU4"/></div> </div></div>

IART

The regenerative medicine market is projected to grow from $32.1 billion in 2023 to $531.7 billion by 2033, at a CAGR of 32.4%. Key drivers include the rise in chronic diseases and an aging population, while high treatment costs pose challenges. The cell therapy segment leads in revenue, with oncology applications also prominent. North America and Europe are expected to maintain market leadership, but Asia-Pacific is set for rapid growth. Recent developments include strategic alliances and acquisitions among key players like Integra LifeSciences and Gilead Sciences.

prnewswire

Integra LifeSciences

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares US Pharma

Franklin Genomic Adv ETF

Wisdomtree BioRevolution Fund ETF

Gilead Sciences, Inc.

Running Oak Efficient Growth ETF

iShares Global Healthcare

Gilead Sciences

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Intellia Therap

iShares Genomics Immunology and Healthcare ETF

CRISPR Therap

VG Health

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

11:58 ETRegenerative Medicine Market to Reach $531.7 billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research